TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT02523014: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Sponsor: Alliance for Clinical Trials in Oncology · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 124 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,556,400

Rescue Site Savings

+$1,693,200

Unlock Full NCT02523014 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT02523014 Rescue Dossier →